MARKET

MGNX

MGNX

MacroGenics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.26
-0.33
-2.85%
Closed 16:45 01/17 EST
OPEN
11.66
PREV CLOSE
11.59
HIGH
11.85
LOW
11.19
VOLUME
401.39K
TURNOVER
--
52 WEEK HIGH
32.32
52 WEEK LOW
7.43
MARKET CAP
551.27M
P/E (TTM)
-3.1233
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MGNX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MGNX News

  • Eli Lilly ends deal with NextCure worth up to $1.4B for the local biotech
  • American City Business Journals.6d ago
  • MacroGenics to Present at the J.P. Morgan Healthcare Conference
  • GlobeNewswire.01/13 12:30
  • MacroGenics Outlines Corporate Priorities for 2020
  • GlobeNewswire.01/09 21:30
  • Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug.
  • American City Business Journals.01/06 22:14

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About MGNX

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.
More

Webull offers MacroGenics Inc (MGNX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.